Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1912-1918, 2020.
Article
ي Zh
| WPRIM
| ID: wpr-879992
المكتبة المسؤولة:
WPRO
ABSTRACT
OBJECTIVE@#To analyze the efficacy of rituximab combined with CHOP/EPOCH regimen for treatment of diffuse large B-cell lymphoma(DLBCL) patients, and to explore the high risk factors of refractory and relapsed patients.@*METHODS@#The clinical data of 72 patients with de novo DLBCL from December 2012 to December 2018 in the Department of Hematology, Zhongda Hospital Affiliated to Southeast University were retrospectively analyzed. The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH was analyzed, and survival analysis was conducted to explore the risk factors influencing refractory recurrence.@*RESULTS@#45 cases among 72 patients achieved complete remission (CR), 11 cases achieved partial remission (PR), the total remission rate was 77.78%. 25 cases (34.2%) refractory and relapsed. Single factor analysis showed that the B symptoms, low Hb, high NLR, low MLR, high β@*CONCLUSION@#The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH regimen is high, but about one third of the patients still show refractory and relapsed. B Symptoms, anemia, high β
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Prognosis
/
Vincristine
/
Prednisone
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Retrospective Studies
/
Lymphoma, Large B-Cell, Diffuse
/
Treatment Outcome
/
Cyclophosphamide
/
Etoposide
نوع الدراسة:
Observational_studies
/
Prognostic_studies
المحددات:
Humans
اللغة:
Zh
مجلة:
Journal of Experimental Hematology
السنة:
2020
نوع:
Article